Log In

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

Forgot your password?

Don't have an account? Sign Up Here

Join Us

Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more.

I agree to TheMaven'sTerms andPolicy

Already have an account? Login here

JIM CRAMER INVESTING PERSONAL FINANCE RETIREMENT CRYPTO MARKETS HOW-TO VIDEO FINANCIAL ADVISOR CENTER TECHNOLOGY

Biotechnology

Wall Street Bull Market

New Berkshire Boss, Dell, Vaxart, Ethereum – On TheStreet Monday

Vaxart Lead

Vaxart Slips Ahead of Oral COVID Variant-Fighting Vaccine Results

By M. Corey Goldman

AbbVie Lead

AbbVie Posts First-Quarter Earnings Beat and Raises Guidance

By M. Corey Goldman

Jim Cramer Explains Why He's in Favor of Merck's Acquisition of Cubist

Merck Posts Earnings Miss, Keytruda Sales Jump but Miss Forecasts

By M. Corey Goldman

Jim Cramer: I Don't Want to Give Up On Amgen

Amgen Drops; FDA Urges Post-Marketing Study for Drug Candidate

By Tony Owusu

Zymergen Lead

Zymergen Jumps in Debut After Upsized Initial Public Offering

By Tony Owusu

Closing Bell: Vertex Pharmaceuticals Up on String of Upgrades; Records for Wall Street

Crispr Gets $900M From Vertex, Tied to Gene-Editing Therapy

By Dan Weil

Biotech Premarket Movers: Cempra, Tesaro, Editas

Editas Medicine Falls as Goldman Sachs Initiates the Stock at Sell

By Tony Owusu

Zymergen Lead

Zymergen, Biofacturing Firm, Kicks Off Roadshow for IPO

By Rob Lenihan

Coronavirus: Pfizer And BioNtech To Seek Emergency US Approval 'within Days' After Better-than-expected Test Results

Pfizer Expanding Production of COVID-19 Vaccine by 10%

By Tom Bemis

Illumina Sinks on Fourth-Quarter Earnings Miss

Illumina Rises as Strong Sales Spur Analyst to Boost Revenue Target

By M. Corey Goldman

Vaccine Lead

Don't Believe the Hype About COVID 'Super Strains,' Says Top Virologist

By Adam Smith

Humanigen Lead

Humanigen Higher on Progress With COVID Treatment

By Dan Weil

Biotech movers: Ionis Drops After GSK Bows Out of Partnership

Ionis Plunges After Roche Ends Phase 3 Huntington’s Drug Trial

By M. Corey Goldman

AstraZeneca Gets 'Complete Response Letter' From FDA on Hyperkalaemia Treatment

AstraZeneca, Boeing, Fed - What to Watch Tuesday

Enzo CEO: Clinical Business Heating Up, Patents Wins Will Continue

Enzo Biochem Blasts Higher as Revenue Jumps 62%

By Dan Weil

AstraZeneca's Big Bet on Oncology May Finally Pay Off

AstraZeneca COVID Jab Suspended by More Countries on Clot Concerns

By M. Corey Goldman

Covid Testing Lead

GenMark and Roche Tie the Knot as Roche Jumps Into Diagnostics

CK Life Is Poised To Distribute Test Kits To Help Hong Kong Speed Up Coronavirus Diagnosis As Covid-19 Pandemic Continues Spreading

Roche Says its Buying GenMark for $1.8 Billion

By M. Corey Goldman

Hong Kong Health Experts Say Delay To AstraZeneca Vaccine Effort Will Not Hinder Government Plans To Secure Covid-19 Shots

AstraZeneca Says Shot Is Safe After Worry Of Blood Clotting Risks

By Adam Smith

Vir Biotechnology Lead

Vir Biotech Higher on Phase 3 Progress With COVID Antibody Drug

By Dan Weil

Fosun Hopes To Launch BioNTech And Pfizer's Covid-19 Vaccine In China At The Same Time As US And Europe, Guo Guangchang Says

Pfizer-BioNTech Vaccine Shows Promise Neutralizing Variants

Acadia Pharma Jumps on Positive Data From Depression Treatment Candidate

Acadia Analysts Cut Targets as FDA Sees Application Deficiencies

By Tony Owusu

Coronavirus: Pfizer And BioNtech To Seek Emergency US Approval 'within Days' After Better-than-expected Test Results

Pfizer COVID Vaccine Neutralizes Brazil Variant, Study Finds

By M. Corey Goldman

Terms Of Use
Privacy Policy
Advertise
Market Holidays 2021
Customer Service
Data
Topic Archive
Subscriptions

© 2021 TheStreet, Inc. All rights reserved. Action Alerts PLUS is a registered trademark of TheStreet, Inc.